GSK plots return to growth with launch of 20 new drugs by 2020
November 4, 2015Research and Development, Sales and Marketing GSK, Sir Andrew Witty, financial results, product pipeline
GSK has set out plans to boost its flagging performance with the launch of up to 20 new drugs by …
Drugs later in development ‘winning the race to market’
November 4, 2015Research and Development R&D, drug approval, drug development, market exclusivity
Nearly all later entrants to drug classes were in clinical testing or regulatory review before first-in-class approval, according to the …
Pfizer approached GSK for takeover before Allergan
November 4, 2015Research and Development, Sales and Marketing Allergan, GSK, Pfizer, financial results, product pipeline
Pfizer had a takeover approach rejected by fellow pharma giant GlaxoSmithKline, before turning its attentions to Allergan, it has emerged. …
Bristol-Myers Squibb enters academic R&D tie-up
November 4, 2015Research and Development BMS, Bristol-Myers Squibb, Cardioxy, John Hopkins, acquisition, immunooncology, job losses
Bristol-Myers Squibb and The Johns Hopkins University have entered into a collaboration agreement, as part of the pharma firm’s rare …
Novo Nordisk forms academic partnership with Washington Uni
November 4, 2015Research and Development Novo Nordisk, diabetes, obesity
Novo Nordisk has launched a new research collaboration with researchers at the University of Washington, to develop new drugs for …
Putting off-patent drugs back to work
November 4, 2015Research and Development, Sales and Marketing Off-Patent Drugs Bill, Professor Paul Workman, The ICR, The ICR London, drug repurposing, patents
Six clinicians here at The Institute of Cancer Research, London, have joined colleagues from across the UK in writing to …
GSK and Merck to study immunotherapy combo in solid tumours
November 3, 2015Research and Development GSK, Merck, immunooncology, immunotherapy, keytruda, phase I
GSK and Merck will start a Phase I clinical trial in humans to evaluate GSK’s investigational cancer drugs with the …
Pharma R&D hub BioCity appoints new CFO
November 3, 2015Manufacturing and Production, Research and Development, Sales and Marketing BioCity, Paul Oliver
BioCity, the UK bioscience incubator, has appointed Paul Oliver as chief financial officer as it prepares to grow across its …
Sanofi claims $109m impact on revenue following recall
November 3, 2015Manufacturing and Production Sanofi, finance, maufacturing, product recall
As Sanofi recalls its Auvi-Q epinephrine injection for the treatment of severe allergic reactions – after the company found the …
EU plans export waiver for pharma manufacturing
November 3, 2015Manufacturing and Production EGA, European Commission, biologics, biosimilars, generics, manufacturing, supplementary protection certificates
The European Commission plans to bring in an export waiver for supplementary protection certificates, in order to boost pharma industry …
Sanofi and BioNTech in cancer immunotherapy partnership
November 3, 2015Manufacturing and Production, Research and Development BioNTech, Cancer, Sanofi, immunotherapy
Sanofi and BioNTech have agreed a new multi-year exclusive collaboration and license agreement, to discover and develop up to five …
Mylan appoints a global commercial lead for OTC business
November 3, 2015Manufacturing and Production Mylan, OTC, Ranjan Ray Chaudhuri, over the counter
Mylan has appointed Ranjan Ray Chaudhuri as its new global commercial lead for the company’s over-the-counter (OTC) business. Chaudhuri will …
FDA alleges records cover-up at Chinese Pfizer plant
November 3, 2015Manufacturing and Production FDA, Pfizer, compliance, inspection, manufacturing, production, regulations
The FDA has discovered violations at a Pfizer plant in China, including the use of out-of-date materials and record- keeping …
Featured market report: 3D printing market summary
November 2, 2015Manufacturing and Production 3d printing, manufacturing, medical devices, production
The global 3D printing medical devices market is estimated to grow at a CAGR of 25.3% from 2015 to 2020.The …
Shire to acquire Dyax in $5.9 billion deal
November 2, 2015Manufacturing and Production, Research and Development, Sales and Marketing Dyax, M&A, MA, R&D, Shire, hereditary angioedema, rare disease
Shire has struck a deal to acquire the biotech firm Dyax for $5.9 billion, in order to acquire exclusive rights …
Biopharma firm F-star appoints Dr Neil Brewis as CSO
November 2, 2015Manufacturing and Production, Research and Development F-star, Neil Brewis
F-star, a biopharma company focused on immuno-oncology, has hired Dr Neil Brewis as chief scientific officer. Dr Brewis is a former vice …
Former Deputy Attorney General called in to advise Valeant after fraud allegations
November 2, 2015Medical Communications, Sales and Marketing Mark Filip, Philidor, Valeant, fraud
Valeant Pharmaceuticals’ board of directors has appointed former Deputy Attorney General of the United States Mark Filip to advise the …
Allergan subsidiary president arrested on kickback charges
November 2, 2015Sales and Marketing Allergan, US District Court, Warner Chilcott, fraud, healthcare fraud
Allergan subsidiary Warner Chilcott will plead guilty to a US felony charge of healthcare fraud, and settle a case of …
European Commission funds €23m project to develop HIV vaccine
November 2, 2015Research and Development, Sales and Marketing BioNTech, European Commission, HIV, R&D, horizon 2020
The European Commission has kicked-off a new €23 million research program to bring together researchers to work on a potential …
Bayer, Regeneron’s Eylea gets additional EU indication
November 2, 2015Research and Development, Sales and Marketing Bayer, Eylea, Regeneron
The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
